ADORA2A and breast carcinoma: For example, dexmedetomidine, a highly selective α2-AR agonist, has been reported to significantly increase the proliferation, migration, and invasion of the breast cancer cell lines MCF-7 and MDA-MB-231 in vitro by activating the α2-AR and downstream signaling pathways (66–68).